Strados Labs

12/09/2025

Today we’re celebrating a major milestone in making every breath count: the RESP® Biosensor has officially captured 50 million breaths!

This achievement wouldn’t be possible without our research collaborations in 2025, from academic medical centers, pediatric and adult hospitals, and pharmaceutical companies who have partnered with us to strengthen insight into patient treatment response and respiratory status.

Here’s to the next 50 million breaths and to continuing to make every breath count!

12/04/2025

Cough is one of the most distressing and persistent symptoms for people living with bronchiectasis.

Persistent cough often reflects mucus burden, airway inflammation, and ongoing exacerbation risk. Yet, in both routine care and clinical research, cough is still frequently assessed through patient recall alone.

As new therapies emerge, understanding cough patterns with greater clarity can help better characterize disease progression, treatment response, and patient quality of life.

Learn why cough matters in bronchiectasis and how objective cough measurement can advance care and clinical research: https://stradoslabs.com/bronchiectasis/

12/02/2025

Respiratory virus season has arrived, and cases of COVID-19, influenza, and RSV are expected to rise as colder months set in.

According to the CDC’s 2025–26 outlook, hospitalizations are projected to reach levels similar to last season. Public health experts emphasize vaccination as the best protection—especially for older adults, children, and those with chronic respiratory conditions. Read more from ABC News: https://bit.ly/3JPa66L

As respiratory viruses continue to challenge healthcare systems, tools like our RESP® Biosensor that support prevention, early detection, and ongoing monitoring remain critical for improving outcomes.

Here's what to know about the COVID-19, flu and RSV vaccines available for respiratory virus season including who is eligible and where to get them.

11/27/2025

We’re thankful for the clinicians and researchers advancing respiratory care, the patients who inspire continued progress, and our employees whose commitment makes our mission possible.

Wishing everyone a Happy Thanksgiving!

11/26/2025

Our latest abstract is now available to view online!

We’re pleased to share that the digital poster version of our latest abstract is now live. This research explores the feasibility of measuring cough sound intensity (amplitude), an emerging objective measure of cough severity, using the RESP® Biosensor in real-world settings.

Expanding beyond cough frequency, this work highlights how additional acoustic measures may provide more qualitative information on individual coughs, offering deeper insight into cough burden and disease impact.

🔗 View our digital poster: https://bit.ly/4oXJhwB

11/25/2025

Strados Labs is proud to be participating in the Digital Medicine Society (DiMe) initiative to develop a core set of digital measures for pediatric rare diseases.

This project brings together leaders across clinical research, advocacy, technology, and regulation to define standardized digital endpoints that can:

- Accelerate therapeutic development for children with rare conditions
- Reduce burden for families through more flexible, real-world data collection
- Guide the design of digital tools that are appropriate and meaningful for pediatric populations

We’re proud to contribute to this important effort and look forward to the impact it will have on future pediatric rare disease research.

Learn more about the project: https://datacc.dimesociety.org/core-digital-measures-pediatric-rare-diseases/

11/21/2025

Digital health technologies are redefining respiratory research and care, expanding access through home monitoring and decentralized clinical trials that bring participation closer to patients.

A recent article from AJMC - The American Journal of Managed Care underscores both the promise and complexity of this shift. Experts agree that digital tools must be validated not only for accuracy, but also for how well they integrate into patients’ daily lives and clinical workflows. Learn more: https://bit.ly/4nJSd7w

Our clinically validated RESP® Biosensor reflects that approach. It continuously and passively captures lung sounds in a wireless, patient-friendly form factor that integrates into daily life. By collecting a robust combination of respiratory and physiological data, including time-stamped cough and wheeze events, it gives clinical teams a more complete view of respiratory health in both care and research settings.

Digital health technologies enhance respiratory care through decentralized clinical trials and home monitoring, expanding access and improving patient engagement.

11/19/2025

Today is World COPD Day, a global effort led by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) to increase awareness, improve care, and support the millions of people living with COPD.

This year’s theme, “Short of Breath, Think COPD,” highlights how often COPD goes unrecognized. Despite being one of the leading causes of illness and death worldwide, many individuals experience symptoms for years before receiving a correct diagnosis.

GOLD emphasizes the importance of noticing early signs such as:

- Persistent shortness of breath
- Chronic cough or sputum production
- Frequent chest infections
- Ongoing exposure to risk factors like to***co smoke, biomass fuels, or occupational irritants

COPD is preventable and treatable, but identifying it early and managing proactively is essential. World COPD Day is an important reminder to elevate education, reduce stigma, and ensure people at risk have access to evaluation and care.

11/17/2025

That’s a wrap on the 2025 , marking the Pulmonary Fibrosis Foundation’s 25th anniversary and recognizing the continued evolution of pulmonary fibrosis (PF) and interstitial lung disease (ILD) research and care.

As we close out a full conference season, we’re reflecting on the broader conversations happening in respiratory research and how innovations like continuous lung acoustics monitoring with our RESP® Biosensor can play a role in improving disease surveillance, management of chronic respiratory conditions, and evaluation of treatment response.

11/12/2025

Tomorrow we are excited to join clinicians, researchers, and patient advocates in Chicago for Pulmonary Fibrosis Foundation's , the leading event advancing pulmonary fibrosis (PF) and interstitial lung disease (ILD) science and awareness.

We’re honored to contribute to this collaborative effort to expand education, improve treatment understanding, and accelerate progress toward better outcomes for people living with these conditions.

Our team will share data on cough sound intensity measured with the RESP® Biosensor, exploring its potential as a new objective cough measure in respiratory research.

We hope to see you there!

11/05/2025

A cough that won’t go away is often dismissed, but for some, it’s the first sign of a serious lung condition.

A recent Pulmonary Fibrosis News article shares how idiopathic pulmonary fibrosis (IPF) can take months, or even years, to diagnose. Because symptoms like cough and shortness of breath are common and nonspecific, patients often face misdiagnoses and delays that can impact treatment options and outcomes.

At Strados Labs, we’re helping clinicians identify and track lung disease earlier through objective, continuous respiratory sound data. By making changes in lung health easier to detect, we aim to support faster diagnosis and more informed care for patients with conditions like IPF.

Read the full article here: https://bit.ly/4o4uIqc

Columnist Sam Kirton's diagnostic journey was relatively short compared with that of other idiopathic pulmonary fibrosis (IPF) patients.

11/04/2025

In less than two weeks, our team is gearing up for the Pulmonary Fibrosis Foundation's (Nov 13–15), a global gathering focused on advancing research, education, and care for patients with pulmonary fibrosis (PF) and interstitial lung disease (ILD).

Global Director Shane Krauss and Director of Data Science Tom deLaubenfels will share our latest research on cough sound amplitude as an emerging objective measure, highlighting the potential of the RESP® Biosensor to offer new insights into cough burden in patients with PF and ILD.

If you’ll be at the Summit, message us to connect or learn more about the event: https://bit.ly/48e5n8A